Ann Merrifield

President  & Chief Executive Officer

Ms. Merrifield has spent much of her career leading the development of high growth, profitable biotechnology businesses. During an 18-year tenure at Genzyme Corporation, a diversified, global biotechnology company, Ms. Merrifield served as President of Genzyme Biosurgery, where she led global business strategy across a complex portfolio of biologics, therapeutic devices and combination products; and as Vice President of Marketing, General Manager and then President of Genzyme Genetics, where she played an instrumental role in developing and shaping its diagnostic business. Prior to Genzyme, Ms. Merrifield was a Partner at Bain and Company, a global strategy consulting firm, and an Investment Officer at Aetna Life & Casualty. She serves as Trustee and Director on several boards including Partners Continuing Care, the non-acute care services division of Partners HealthCare; the YMCA of Greater Boston; and MassMutual Premier, Select and MML Series Investment Funds. Ms. Merrifield earned a Bachelor of Arts in Zoology and a Master of Education from The University of Maine, and a Master of Business Administration from the Amos Tuck School of Business at Dartmouth College.

John W. Czajka, Ph.D., M.B.A.

Vice President, Business Development

Dr. Czajka has more than 15 years of experience in the field of molecular diagnostics, and has worked in the areas of foodborne pathogen and biowarfare threat identification as well as veterinary and human clinical diagnostics.  Dr. Czajka joined PathoGenetix after nine years at Smiths Detection, first as a research scientist developing PCR assays for biowarfare threats, then progressing to R&D Program Manager, Vice President of Technology Assessment and Acquisition, and finally Director of Business Development for Smiths Detection Diagnostics.  Prior to Smiths Detection, Dr. Czajka worked for Dupont Qualicon developing PCR assays and molecular typing technologies for foodborne pathogens.  Dr. Czajka holds a Ph.D. from Cornell University, Department of Food Science with a focus on foodborne pathogen detection and molecular diagnostics, and an M.B.A. in Technology Management from the University of Phoenix.

John A. Luckey, Ph.D., M.B.A.

Vice President, Engineering

Dr. Luckey has more than 20 years of experience in biotechnology systems research and development with both large and small diagnostic companies. Prior to joining PathoGenetix, he was Technical Projects Director with Roche NimbleGen, working with the Applied Science and Molecular Diagnostics divisions, and Director of Platform Development, directing research and development for the company’s core DNA microarray synthesis technology. Prior to Roche, Dr. Luckey managed software development and instrumentation design engineering activities at OpGen Technologies, and product development, engineering and molecular biology projects at MJ Research. In 1994, he founded GeneSys Technologies to market the BaseStation DNA Fragment Analyzer, an ultrathin gel electrophoresis system that he had designed, developed and patented. Dr. Luckey holds a Ph.D. in Analytical Chemistry and an M.B.A. in Executive Management from the University of Wisconsin, Madison.

Rudolf Gilmanshin, Ph.D.

Vice President, Research and Development

Dr. Gilmanshin joined PathoGenetix in June of 1998 as the first employee of the company. He has made substantial contributions to the development of all technology platforms. Dr. Gilmanshin came to PathoGenetix from Albert Einstein College of Medicine, New York, where he studied structural transformations of protein molecules. He brings over 35 years of research experience, including work at Los Alamos National Laboratory, various universities, and the Russian Academy of Sciences where he studied protein folding, molecular films, and dynamics of biomolecular systems. Dr. Gilmanshin attained his Ph.D. in Molecular Biophysics from the Institute of Protein Research at the Russian Academy of Sciences. He also holds an M.S. in Physics of Fast Processes from the Moscow Institute of Physics and Technology and has authored 41 papers and several patents.

Donald M. Crothers, Ph.D.

Scientific Advisor

Dr.Crothers is Sterling Professor of Chemistry Emeritus at Yale University, and Venture Partner with Excel Venture Management. He was Chairman of the Yale Chemistry Department for 4 three-year terms. He has authored 280 scientific publications, including three textbooks, and holds 14 patents. He was a cofounder of Molecular Diagnostics in West Haven, Connecticut in 1982, which was bought by Bayer in 1992, and Chief Scientist at GeneOhm Sciences in San Diego, from 2001-2006, which was acquired by Becton Dickinson. He is a member of the National Academy of Science and the American Academy of Arts and Sciences.